2 months ago
JNJ
AnalystsDavid RisingerDavid Risinger's Stock Forecasts
AnalystsDavid Risinger
Analyst Ranking
Top 9%
#446 out of 4923 analysts
Average Return
+18.24%
Win Rate
62%40 out of 65
Risk vs Reward
Poor
Good
David Risinger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Horizon Therapeutics Public Ltd CoHZNP | +184.14% | $31.85 | $90.50 | 2020-04-01 - 2021-04-01 | Strong Buy |
Centessa Pharmaceuticals PLCCNTA | +175.64% | $3.90 | $10.75 | 2023-03-16 - 2024-03-15 | Buy |
Roivant Sciences LtdROIV | +164.66% | $3.65 | $9.66 | 2022-05-22 - 2023-05-22 | Buy |
Roivant Sciences LtdROIV | +124.28% | $4.49 | $10.07 | 2022-06-28 - 2023-06-28 | Buy |
Eli Lilly & CoLLY | +92.48% | $405.81 | $781.10 | 2023-04-30 - 2024-04-30 | Buy |
David Risinger Analyst Color
Get additional color on David Risinger's coverage of popular stocks
2 years ago
LLY
2 years ago
ABBV
3 years ago
PFE
3 years ago
JNJ
David Risinger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Johnson & JohnsonJNJ | 4 | Hold | $153.00 | +0.16% | Downgrades | 2 months ago |
Vertex Pharmaceuticals IncVRTX | 4 | Hold | $503.00 | +12.98% | Downgrades | 2 months ago |
Regeneron Pharmaceuticals IncREGN | 8 | Buy | $834.00 | +58.86% | Upgrades | 5 months ago |
Abbvie IncABBV | 5 | Buy | $206.00 | +10.98% | Upgrades | 7 months ago |
Bristol Myers Squibb CoBMY | 4 | Buy | $73.00 | +57.70% | Upgrades | 8 months ago |
Tectonic Therapeutic IncTECX | 2 | Buy | $69.00 | +247.26% | Maintains | 8 months ago |
Tenax Therapeutics IncTENX | 1 | Buy | $16.00 | +177.78% | Initiates Coverage On | 8 months ago |
Oruka Therapeutics IncORKA | 2 | Buy | $44.00 | +292.51% | Initiates Coverage On | 9 months ago |
Vaxcyte IncPCVX | 2 | Buy | $153.00 | +370.62% | Maintains | 10 months ago |
Theravance Biopharma IncTBPH | 3 | Hold | $10.00 | -9.34% | Downgrades | a year ago |
Hillevax IncHLVX | 2 | Hold | $2.00 | +0.50% | Downgrades | a year ago |
Anaptysbio IncANAB | 1 | Buy | $47.00 | N/A | Initiates Coverage On | a year ago |
Amgen IncAMGN | 4 | Buy | $318.00 | N/A | Upgrades | 2 years ago |
Centessa Pharmaceuticals PLCCNTA | 2 | Buy | $11.00 | N/A | Maintains | 2 years ago |
Eli Lilly & CoLLY | 12 | Buy | $458.00 | N/A | Maintains | 2 years ago |
Halozyme Therapeutics IncHALO | 3 | Hold | $42.00 | N/A | Downgrades | 2 years ago |
Gilead Sciences IncGILD | 3 | Hold | $91.00 | N/A | Maintains | 2 years ago |
Pfizer IncPFE | 9 | Hold | $48.00 | N/A | Maintains | 2 years ago |
Roivant Sciences LtdROIV | 4 | Buy | $10.00 | N/A | Maintains | 3 years ago |
Horizon Therapeutics Public Ltd CoHZNP | 7 | Hold | $116.50 | N/A | Downgrades | 3 years ago |
Radius Health IncRDUS1 | 2 | Hold | $10.00 | N/A | Maintains | 3 years ago |
Organon & CoOGN | 1 | Hold | $33.00 | N/A | Initiates Coverage On | 4 years ago |
Jazz Pharmaceuticals PLCJAZZ | 3 | Hold | $176.00 | N/A | Maintains | 4 years ago |
Viatris IncVTRS | 1 | Hold | $16.00 | N/A | Maintains | 4 years ago |
Perrigo Co PLCPRGO | 5 | Hold | $45.00 | N/A | Maintains | 4 years ago |
Endo International PLCENDPQ | 2 | Strong Sell | $7.00 | N/A | Maintains | 4 years ago |
Bausch Health Companies IncBHC | 1 | Hold | $35.00 | N/A | Maintains | 4 years ago |
Elanco Animal Health IncELAN | 2 | Strong Buy | $31.00 | N/A | Upgrades | 5 years ago |
Royalty Pharma PLCRPRX | 1 | Hold | $51.00 | N/A | Initiates Coverage On | 5 years ago |
Zoetis IncZTS | 2 | Hold | $125.00 | N/A | Maintains | 5 years ago |
Teva Pharmaceutical Industries LtdTEVA | 7 | Strong Sell | $8.00 | N/A | Maintains | 5 years ago |
Merck & Co IncMRK | 6 | Strong Buy | $89.00 | N/A | Maintains | 5 years ago |
Alkermes PLCALKS | 1 | Hold | $16.00 | N/A | Maintains | 5 years ago |
Allergan PLCAGN | 6 | Hold | $156.00 | N/A | Downgrades | 6 years ago |
Amneal Pharmaceuticals IncAMRX | 1 | Hold | $18.00 | N/A | Downgrades | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.